Novo Nordisk's net profit increased by 12% in the first nine months of 2021
November 03 2021 - 2:30AM
Novo Nordisk's net profit increased by 12% in the first nine months
of 2021
Financial report for the period 1 January 2021 to 30 September
2021
3 November
2021
Novo Nordisk's net profit increased by 12% in the first
nine months of 2021
- Operating profit increased by 5% in
Danish kroner and by 12% at constant exchange rates (CER).
- Sales increased by 8% in Danish
kroner and by 13% at CER to DKK 102.5 billion. Sales in
International Operations increased by 10% in Danish kroner (13% at
CER), and sales in North America Operations increased by 6% in
Danish kroner (13% at CER).
- Sales within Diabetes and Obesity
care increased by 10% in Danish kroner to DKK 88.0 billion (15% at
CER), driven by GLP-1 growth of 24% in Danish kroner (30% at CER)
reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew
by 41% in Danish kroner (49% at CER) and Biopharm sales remained
unchanged in Danish kroner (increased by 4% at CER).
- Sales in the third quarter increased
by 15% in Danish kroner (15% at CER) compared to the third quarter
of 2020. Sales growth was driven by diabetes GLP-1 growth of 30% in
Danish kroner (31% at CER) and Obesity care growth of 79% in Danish
kroner (82% at CER) reflecting market expansion and the launch of
Wegovy™ in the US.
- Within R&D, Novo Nordisk
initiated phase 3 development with both oral semaglutide 50 mg for
the treatment of obesity and with ziltivekimab in cardiovascular
disease during the third quarter.
- On 29 October, the 2021 outlook was raised with sales growth
and operating profit growth now both expected to be 12-15% at CER.
Sales and operating profit growth reported in Danish kroner is now
expected to be 3 and 4 percentage points lower than at CER,
respectively. The ongoing share buyback programme is expanded by
DKK 2.0 billion to DKK 20 billion.
PROFIT AND LOSS |
9M 2021 |
9M 2020 |
Growthas reported |
Growthat CER* |
DKK million |
|
|
|
|
Net sales |
102,467 |
94,808 |
8% |
13% |
Operating
profit |
45,010 |
42,948 |
5% |
12% |
|
|
|
|
|
Net profit |
36,865 |
32,820 |
12% |
N/A |
Diluted earnings per share (in DKK) |
15.98 |
14.00 |
14% |
N/A |
* CER: Constant exchange rates (average 2020).
Lars Fruergaard Jørgensen, president and CEO: "We are very
pleased with the sales growth in the first nine months of 2021
which has enabled us to raise our outlook for the full year. The
growth is driven by all geographical areas and by all therapy
areas, in particular by accelerated growth of our portfolio of
GLP-1 treatments for diabetes and obesity. In the US, the initial
demand for Wegovy™ has significantly exceeded our expectations,
underscoring the high unmet need for people living with obesity.
With the initiation of two phase 3 programmes in the third quarter,
we continue to expand our late-stage clinical pipeline."
On 3 November 2021 at 13.00 CET, corresponding to 08.00 AM EDT,
an earnings call will be held. Investors will be able to listen in
via a link on novonordisk.com, which can be found under
‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Financial
calendar |
|
2 February
2022 |
Financial
statement for 2021 |
3 March 2022 |
Capital Markets
Day in Copenhagen, Denmark |
24 March
2022 |
Annual General
Meeting |
4 May 2022 |
Financial
statement for the first three months of 2022 |
4 August
2022 |
Financial
statement for the first six months of 2022 |
2 November
2022 |
Financial
statement for the first nine months of 2022 |
Contacts for further information |
|
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079
3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077
6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Further information about Novo Nordisk is available on
novonordisk.com.
Company announcement No 66 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024